{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:12:13Z","timestamp":1793257933643,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kiora Pharmaceuticals, Inc."},{"name":"Kiora Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A small azobenzene photoswitch molecule (KIO-301), designed to confer light responsiveness to retinal ganglion cells, was evaluated for safety and feasibility in a first-in-human, phase 1, gene-agnostic, open-label, dose-escalation clinical trial in individuals with advanced retinitis pigmentosa (RP). KIO-301 was administered by intravitreal injection to 12 eyes of 6 participants. The primary outcome was ocular and systemic safety over 30\u2009days. Secondary and exploratory assessments included functional vision testing, visual acuity, kinetic visual field, functional magnetic resonance imaging and participant-reported outcomes. The primary safety outcome was met, with no serious adverse events or dose-limiting toxicities observed at any point. No drug-related intraocular inflammation occurred, and all ocular adverse events were mild and procedure-related. Exploratory assessments identified variation in light perception and functional vision measures in some participants. Light-evoked blood-oxygen-level-dependent signal changes in visual cortical regions were observed following dosing and showed a temporal pattern compatible with pharmacodynamic activity. Participant-reported quality-of-life scores varied over time. In this small, nonrandomized phase 1 study in individuals with late-stage RP, intravitreal KIO-301 demonstrated an acceptable safety and tolerability profile, supporting the feasibility of photoswitch therapy in advanced RP, and motivating further evaluation in larger trials. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05282953?term=NCT05282953\" ext-link-type=\"uri\">NCT05282953<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04317-6","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:02:08Z","timestamp":1776157328000},"page":"1865-1870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-4076","authenticated-orcid":false,"given":"Robert J.","family":"Casson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen D.","family":"Barras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Strem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gregorio-King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-9389","authenticated-orcid":false,"given":"Richard H.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-3659","authenticated-orcid":false,"given":"Russell N.","family":"Van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"4317_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0002-9394(84)90636-6","volume":"97","author":"CH Bunker","year":"1984","unstructured":"Bunker, C. H., Berson, E. L., Bromley, W. C., Hayes, R. P. & Roderick, T. H. Prevalence of retinitis pigmentosa in Maine. Am. J. Ophthalmol. 97, 357\u2013365 (1984).","journal-title":"Am. J. Ophthalmol."},{"key":"4317_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/13816810.2021.1913610","volume":"42","author":"RC Heath Jeffery","year":"2021","unstructured":"Heath Jeffery, R. C. et al. Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genet. 42, 431\u2013439 (2021).","journal-title":"Ophthalmic Genet."},{"key":"4317_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41433-020-0864-6","volume":"34","author":"F Rahman","year":"2020","unstructured":"Rahman, F., Zekite, A., Bunce, C., Jayaram, H. & Flanagan, D. Recent trends in vision impairment certifications in England and Wales. Eye (Lond.) 34, 1271\u20131278 (2020).","journal-title":"Eye (Lond.)"},{"key":"4317_CR4","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/j.ajhg.2025.08.017","volume":"112","author":"C Rivolta","year":"2025","unstructured":"Rivolta, C. et al. RetiGene, a comprehensive gene atlas for inherited retinal diseases. Am. J. Hum. Genet. 112, 2253\u20132265 (2025).","journal-title":"Am. J. Hum. Genet."},{"key":"4317_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41591-022-01862-8","volume":"28","author":"RN Van Gelder","year":"2022","unstructured":"Van Gelder, R. N. et al. Regenerative and restorative medicine for eye disease. Nat. Med. 28, 1149\u20131156 (2022).","journal-title":"Nat. Med."},{"key":"4317_CR6","doi-asserted-by":"publisher","first-page":"10748","DOI":"10.1021\/acs.chemrev.7b00723","volume":"118","author":"I Tochitsky","year":"2018","unstructured":"Tochitsky, I., Kienzler, M. A., Isacoff, E. & Kramer, R. H. Restoring vision to the blind with chemical photoswitches. Chem. Rev. 118, 10748\u201310773 (2018).","journal-title":"Chem. Rev."},{"key":"4317_CR7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/archopht.1992.01080230134038","volume":"110","author":"JL Stone","year":"1992","unstructured":"Stone, J. L., Barlow, W. E., Humayun, M. S., de Juan, E. Jr & Milam, A. H. Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa. Arch. Ophthalmol. 110, 1634\u20131639 (1992).","journal-title":"Arch. Ophthalmol."},{"key":"4317_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.neuron.2014.01.003","volume":"81","author":"I Tochitsky","year":"2014","unstructured":"Tochitsky, I. et al. Restoring visual function to blind mice with a photoswitch that exploits electrophysiological remodeling of retinal ganglion cells. Neuron 81, 800\u2013813 (2014).","journal-title":"Neuron"},{"key":"4317_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1021\/cn200037p","volume":"2","author":"A Mourot","year":"2011","unstructured":"Mourot, A. et al. Tuning photochromic ion channel blockers. ACS Chem. Neurosci. 2, 536\u2013543 (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"4317_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep45487","volume":"7","author":"I Tochitsky","year":"2017","unstructured":"Tochitsky, I., Trautman, J., Gallerani, N., Malis, J. G. & Kramer, R. H. Restoring visual function to the blind retina with a potent, safe and long-lasting photoswitch. Sci. Rep. 7, 45487 (2017).","journal-title":"Sci. Rep."},{"key":"4317_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neuron.2016.08.038","volume":"92","author":"I Tochitsky","year":"2016","unstructured":"Tochitsky, I. et al. How azobenzene photoswitches restore visual responses to the blind retina. Neuron 92, 100\u2013113 (2016).","journal-title":"Neuron"},{"key":"4317_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.gim.2021.10.013","volume":"24","author":"AC Britten-Jones","year":"2022","unstructured":"Britten-Jones, A. C. et al. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: a systematic review. Genet. Med. 24, 521\u2013534 (2022).","journal-title":"Genet. Med."},{"key":"4317_CR13","doi-asserted-by":"publisher","first-page":"14758","DOI":"10.3390\/ijms232314758","volume":"23","author":"N Martinez-Gil","year":"2022","unstructured":"Martinez-Gil, N. et al. Purinergic receptors P2X7 and P2X4 as markers of disease progression in the rd10 mouse model of inherited retinal dystrophy. Int. J. Mol. Sci. 23, 14758 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"4317_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11302-024-09999-6","volume":"21","author":"SS Ye","year":"2025","unstructured":"Ye, S. S. et al. Purinergic P2X7 receptor involves in anti-retinal photodamage effects of berberine. Purinergic Signal. 21, 675\u2013685 (2025).","journal-title":"Purinergic Signal."},{"key":"4317_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100811","volume":"38","author":"SW Lukowski","year":"2019","unstructured":"Lukowski, S. W. et al. A single-cell transcriptome atlas of the adult human retina. EMBO J. 38, e100811 (2019).","journal-title":"EMBO J."},{"key":"4317_CR16","doi-asserted-by":"publisher","first-page":"1385932","DOI":"10.3389\/fnana.2024.1385932","volume":"18","author":"D Kim","year":"2024","unstructured":"Kim, D., Roh, H., Lee, H. M., Kim, S. J. & Im, M. Localization of hyperpolarization-activated cyclic nucleotide-gated channels in the vertebrate retinas across species and their physiological roles. Front. Neuroanat. 18, 1385932 (2024).","journal-title":"Front. Neuroanat."},{"key":"4317_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer, J. S., Fox, K., Jaillon, P. & Lerebours, G.Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107, 817\u2013823 (2003).","journal-title":"Circulation"},{"key":"4317_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49999-w","volume":"9","author":"K Hull","year":"2019","unstructured":"Hull, K. et al. Photopharmacologic vision restoration reduces pathological rhythmic field potentials in blind mouse retina. Sci. Rep. 9, 13561 (2019).","journal-title":"Sci. Rep."},{"key":"4317_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7423","volume":"12","author":"P Yu-Wai-Man","year":"2020","unstructured":"Yu-Wai-Man, P. et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci. Transl. Med. 12, eaaz7423 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4317_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cbic.202000449","volume":"22","author":"J Morstein","year":"2021","unstructured":"Morstein, J., Impastato, A. C. & Trauner, D. Photoswitchable lipids. ChemBioChem 22, 73\u201383 (2021).","journal-title":"ChemBioChem"},{"key":"4317_CR21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Medical Dictionary for Regulatory Activities (MedDRA) (International Council for Harmonisation, 2024)."},{"key":"4317_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1097\/OPX.0b013e318264e85a","volume":"89","author":"IL Bailey","year":"2012","unstructured":"Bailey, I. L., Jackson, A. J., Minto, H., Greer, R. B. & Chu, M. A. The Berkeley Rudimentary Vision Test. Optom. Vis. Sci. 89, 1257\u20131264 (2012).","journal-title":"Optom. Vis. Sci."},{"key":"4317_CR23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione, C. M. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 119, 1050\u20131058 (2001).","journal-title":"Arch. Ophthalmol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04317-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:03:09Z","timestamp":1779285789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04317-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4317"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04317-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8060107\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.D. and B.M.S. are employees and officers of Kiora Pharmaceuticals, Inc., and hold equity in the company. C.G-K. is an employee of Kiora Pharmaceuticals, Inc., and holds equity in the company. C.C.W. and R.H.K. serve as consultants to Kiora Pharmaceuticals, Inc. C.S. is an employee of Ora, Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}